Illumina, Inc. balance sheet ILMN

As of Sep 27, 2026, Illumina, Inc. had total assets of $6.8 billion. Total assets were up 10.3% from a year earlier. Stockholders' equity was $3.1 billion. It held $1.3 billion in cash and investments against $524.0 million of total debt, net cash of $813.0 million. The current ratio, current assets divided by current liabilities, was 2.63.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line
Q3 FY2026
Sep 27, 2026
Q2 FY2026
Jun 28, 2026
Q1 FY2026
Mar 29, 2026
Q4 FY2025
Dec 28, 2025
Q3 FY2025
Sep 28, 2025
Q2 FY2025
Jun 29, 2025
Q1 FY2025
Mar 30, 2025
Q4 FY2024
Dec 29, 2024
Assets
Cash
1,289
+22.8%
1,040
+11.3%
1,089
-2.2%
1,418
+25.8%
1,050
+20.8%
934
+1.5%
1,113
+0.5%
1,127
+7.5%
Short-term investments
48
-78.9%
128
-42.1%
66
-46.8%
215
+131.2%
228
+225.7%
221
+198.6%
124
93
+1450.0%
Cash and investments
1,337
+4.6%
1,168
+1.1%
1,155
-6.6%
1,633
+33.9%
1,278
+36.1%
1,155
+16.2%
1,237
+11.6%
1,220
+15.7%
Receivables
738
+1.2%
764
+9.0%
738
+5.6%
854
+16.2%
729
+4.3%
701
+9.4%
699
+10.1%
735
+0.1%
Inventory
667
+13.1%
629
+9.4%
611
+13.8%
564
+3.1%
590
+2.8%
575
+2.5%
537
-8.0%
547
-6.8%
Total current assets
3,035
+8.5%
2,834
+7.3%
2,738
+2.4%
3,289
+19.8%
2,796
+17.8%
2,641
+7.4%
2,673
+3.5%
2,746
+5.3%
Property and equipment, net
731
-2.3%
745
-2.5%
755
-3.5%
759
-6.9%
748
-10.1%
764
-11.1%
782
-18.9%
815
-19.1%
Goodwill
1,284
+15.4%
1,284
+15.4%
1,284
+15.4%
1,113
+0.0%
1,113
+0.0%
1,113
+3.2%
1,113
-56.3%
1,113
-56.3%
Total assets
6,812
+10.3%
6,650
+9.2%
6,559
+6.1%
6,644
+5.4%
6,177
+2.7%
6,087
+0.1%
6,182
-38.4%
6,303
-37.7%
Liabilities and equity
Accounts payable
241
+10.6%
230
+15.0%
218
+5.3%
240
+8.6%
218
+14.1%
200
+0.5%
207
+3.0%
221
-9.8%
Total current liabilities
1,156
-41.1%
1,578
+8.0%
1,566
+8.8%
1,585
+2.5%
1,962
+101.2%
1,461
-33.8%
1,440
-2.3%
1,547
-1.5%
Stockholders' equity
3,145
+32.1%
2,838
+25.7%
2,676
+13.0%
2,723
+14.7%
2,381
+12.0%
2,258
+57.2%
2,368
-58.7%
2,373
-58.7%
Debt
Lease liabilities
524
-10.3%
536
-11.7%
555
-10.0%
564
-10.9%
584
-14.9%
607
-11.6%
617
-21.5%
633
-18.1%
Total debt
524
-10.3%
536
-11.7%
555
-10.0%
564
-10.9%
584
-14.9%
607
-11.6%
617
-21.5%
633
-18.1%
Net cash
813
+17.1%
632
+15.3%
600
-3.2%
1,069
+82.1%
694
+174.3%
548
+78.5%
620
+92.5%
587
+108.9%
Ratios
Current ratio
2.63x
1.80x
1.75x
2.08x
1.43x
1.81x
1.86x
1.78x
Debt to equity
0.17x
0.19x
0.21x
0.21x
0.25x
0.27x
0.26x
0.27x
Debt to EBITDA
0.45x
0.49x
0.53x
0.56x
0.59x
0.40x
—
—
Return on equity
28.46%
29.03%
31.88%
31.22%
29.53%
55.67%
-40.79%
-51.54%
Return on assets
13.14%
12.39%
13.01%
12.79%
11.38%
20.65%
-15.63%
-19.40%
Book value per share
—
—
—
17.80
—
—
—
14.92
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Laboratory Analytical Instruments (SIC 3826)
Listed as
ILMN (Nasdaq)
Fiscal year ends
January 3
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
Large accelerated filer
SEC CIK
1110803
Former names
ILLUMINA INC (until Aug 19, 2019)

Other Laboratory Analytical Instruments companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.